Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309957 | 1.00 | ADRB2 (0.42) | ADRB2AOC3CLK4CYP2A6NPC1 | |
| SCHEMBL6879073 | 1.00 | ADRB2 (0.42) | ADRB2AOC3CLK4CYP2A6NPC1 | |
| SCHEMBL6854217 | 0.83 | HDAC4 (0.35) | NPC1RAB9AHDAC4MEN1POLB | |
| SCHEMBL6881056 | 0.83 | HDAC4 (0.35) | NPC1RAB9AHDAC4MEN1POLB | |
| SCHEMBL6881060 | 0.83 | HDAC4 (0.35) | NPC1RAB9AHDAC4MEN1POLB | |
| SCHEMBL6848093 | 0.82 | CYP1A2 (0.42) | CYP2A6NPC1RAB9APOLBCYP19A1 | |
| SCHEMBL6853694 | 0.82 | CLK4 (0.39) | ADRB2AOC3CLK4CYP2A6CYP19A1 | |
| SCHEMBL6848097 | 0.82 | CYP1A2 (0.42) | CYP2A6NPC1RAB9APOLBCYP19A1 | |
| SCHEMBL6853692 | 0.82 | CLK4 (0.39) | ADRB2AOC3CLK4CYP2A6CYP19A1 | |
| SCHEMBL6848094 | 0.82 | CYP1A2 (0.42) | CYP2A6NPC1RAB9APOLBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005121160-A2 | 11, 12 CYCLIC THIOCARBAMATE MACROLIDE ANTIBACTERIAL AGENTS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050250713-A1 | 11,12-Cyclic thiocarbamate macrolide antibacterial agents | ZHU BIN | 2005-11-10 | — | — | US | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | ADRB2 4390/4885AOC3 1365/4885CLK4 3870/4885 |
| US-20050250713-A1 | 11,12-Cyclic thiocarbamate macrolide antibacterial agents | MRPL21, TTC14, MRPL12 | ADRB2 4761/4885AOC3 4549/4885CLK4 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.